Results 151 to 160 of about 116,083 (186)

A practical approach to better identify NTRK 1-3 fusion-positive mesenchymal neoplasms by pan-Trk immunohistochemistry. [PDF]

Virchows Arch
Haberecker M, Kuerten P, Vetter VK, Malega F, Moch H, Pauli C.   +5 more
europepmc   +1 more source

Advancing the treatment of NTRK-fused pediatric solid tumors: lessons from the ADVL1823 study. [PDF]

Transl Pediatr
Vince CSC, Valera ET.
europepmc   +1 more source

Expanding the histologic spectrum of thyroid neoplasms with NTRK1/2/3 or ALK translocation: a single-center retrospective study of 82 cases. [PDF]

Virchows Arch
Ghossein R, Instrum R, Dogan S, Chongtham N, Mullaney K, Roy D, Shaha A, Tuttle RM, Ganly I, Morris L, Xu B.   +10 more
europepmc   +1 more source

Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer. [PDF]

Cancers (Basel)
Georgescu TA, Georgescu AC, Iacoban SR, Crețoiu D, Copca N, Olinca MV.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

p75NTR and apoptosis: Trk-dependent and Trk-independent effects

Trends in Neurosciences, 1997
The ongoing dissection of the roles of p75NTR and TrkA, -B and -C in neurotrophin signaling has generated a number of apparent paradoxes. Limiting consideration to the role of p75NTR in cell death, a theory is proposed that is based on the following postulates: (1) that p75NTR displays a pro-apoptotic intrinsic (ligand-independent, Trk-independent ...
D E, Bredesen, S, Rabizadeh
openaire   +2 more sources

Trk Receptors

2014
The tropomyosin-related tyrosine kinase (Trk) receptors were initially described as a family of growth factor receptors required for neuronal survival. They have since been shown to influence many aspects of neuronal development and function, including differentiation, outgrowth, and synaptic plasticity.
Katrin, Deinhardt, Moses V, Chao
openaire   +2 more sources

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults

Cancer Genetics, 2022
NTRK fusions drive oncogenesis in a variety of adult cancers. The approval of the first-generation TRK inhibitors, larotrectinib and entrectinib, for any cancer with an NTRK fusion represented a focal point in tumor-agnostic drug development. These agents achieve high response rates and durable disease control, and display intracranial activity.
Guilherme Harada, Alexander Drilon
openaire   +2 more sources

Trk neurotrophin receptor activators

Drug News & Perspectives, 2002
The neurotrophins are a small group of proteins whose binding at the tropomyosin related kinase (Trk) and p75 neurotrophin receptor transmembrane receptors triggers a cascade of signaling events that give rise to neurotrophic responses in neuronal cells and in vivo.
Scott J., Pollack, Sarah J., Harper
openaire   +2 more sources

Neurotrophin receptors (Trk A, Trk B, and Trk C) in the developing and adult human retina

Developmental Brain Research, 1999
In this study, the ontogeny and distribution patterns of three neurotrophin receptors (Trk A, Trk B, and Trk C) were examined in the human retinas. Immunohistochemistry was performed on sections of retina and optic nerve from fetuses (11-24 weeks of gestation, wg), one infant (4-month-old) and two adult (35- and 65-years-old) subjects.
T C, Nag, S, Wadhwa
openaire   +2 more sources